AstraZeneca says detained China head has lawyer

AstraZeneca says detained China head has lawyer, but company still in dark
AstraZeneca's China president Leon Wang, who was detained last month by Chinese authorities, is in touch with a lawyer but the company has very little information about the case, its CEO said on Tuesday.
AstraZeneca says China has detained a senior executive
The company believes Chinese authorities are probing allegations that two current and two former employees had illegally imported cancer drugs.
AstraZeneca talks up US growth as China problems fester
AstraZeneca Plc is increasingly looking to the US for growth as its once fast-expanding China business faces challenges amid a probe that has battered the drugmaker’s share price.
AstraZeneca chief says group takes China probe ‘very seriously’
AstraZeneca chief executive Pascal Soriot said the company took the detention of its China president “very seriously”, as the drugmaker raised its guidance for a second straight quarter on the back of strong sales of cancer medicines.
AstraZeneca CEO says detained China chief has a lawyer but 'we have no information'
AstraZeneca's CEO said on Tuesday that the company's China president Leon Wang, who last month was detained by Chinese authorities, has a lawyer he is in touch with, but "we have no information as a company".
Pharma Giant AstraZeneca Takes China Probes 'Very Seriously'
British pharmaceutical giant AstraZeneca on Tuesday said it takes "very seriously" China's investigations into potential illegal data collection and drug imports by the group that caused the detention of its China boss.
Is AstraZeneca a Buy as It Eyes the Weight Loss Market?
The chart below compares the forward price to earnings (P/E) ratio of AstraZeneca to multiples in a peer set of leading ...
AstraZeneca lifts 2024 outlook after Q3 beat, doubles down on US investments
Drugmaker AstraZeneca lifted its annual sales and profit forecast for the second time this year on Tuesday, helped by strong ...
Outsourcing-pharma2d
AstraZeneca doubles down on US manufacturing with $3.5 billion investment
AstraZeneca has become the latest big pharma company to devote new cash to its US manufacturing muscle this year as it ...
Healthy Returns: AstraZeneca expands U.S. investment plan on confidence in economy
A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news ...
STAT4d
Pharmalittle: We’re reading about 23andMe retrenching, AstraZeneca reworking cancer drug plans, and more
In closing its therapeutics division and laying off 200 people, 23andMe ended an audacious bet it made nearly a decade ago — ...
Reuters4d
AstraZeneca: 450 million pound investment in UK under review amid talks with govt
LONDON, Nov 12 (Reuters) - London-listed drugmaker AstraZeneca (AZN.L), opens new tab said its plan to invest 450 million ...
MM&M4d
AstraZeneca: New drug data, promising earnings and a $3.5B R&D investment
AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease ...
Bisnow3d
AstraZeneca To Invest $3.5B To Grow U.S. Footprint
Cambridge, England-based biopharmaceutical giant AstraZeneca is pouring billions of dollars into properties in the United ...
Business Insider3d
AstraZeneca: Overcoming Short-term Challenges with Robust Long-term Potential
Bernstein analyst Justin Smith maintained a Buy rating on AstraZeneca (AZN – Research Report) today and set a price target of p18,000.00. Justin Smith has given his Buy rating due to a combination ...
This is Money on MSN8h
AstraZeneca bets its future on US growth
Pharmaceuticals giant AstraZeneca is accelerating the shift in its centre of gravity to the US. The move, under chief executive Pascal Soriot, will be a boost for Donald Trump's incoming ...